69876-92-2

Upstream product

• 69876-91-1 4-(2,2,2-trifluoro-N-hexadecylacetamido)benzoic acid 
• 55986-43-1 4-(n-hexadecylamino)benzoic acid 
• 112-82-3 hexadecanyl bromide 
• 94-09-7 p-aminoethylbenzoate 
• 55791-63-4 ethyl 4-(hexadecylamino)benzoate 

Downstream Products

• 70518-03-5 tert-butyl ethyl <4-(2,2,2-trifluoro-N-hexadecylacetamido)benzoyl>malonate 
• 86410-87-9 N-[4-(N'-Acetyl-hydrazinocarbonyl)-phenyl]-2,2,2-trifluoro-N-hexadecyl-acetamide 
• 69877-02-7 ethyl p-[p-(2,2,2-trifluoro-N-hexadecylacetamido)benzamido]benzoate 
• 69876-84-2 N-[4-(hexadecylamino)benzoyl]alanine 
• 70518-01-3 diethyl 2-p-[hexadecylamino]benzoylglutarate 
• 86410-24-4 ethyl 2-<4-(hexadecylamino)benzoyl>propionate 
• 86410-70-0 4-Hexadecylamino-benzoic acid N'-acetyl-hydrazide 
• 86410-66-4 Azepan-1-yl-(4-hexadecylamino-phenyl)-methanone 
• 69876-83-1 1-<4-(hexadecylamino)benzoyl>pyrrolidine 
• 86410-23-3 methyl <4-(hexadecylamino)benzoyl>acetate 
• 69876-76-2 4-Hexadecylamino-N-hydroxy-benzamide 
• 70517-64-5 4-(hexadecylamino)-α-hydroxyacetophenone 
• 86410-88-0 4-[Hexadecyl-(2,2,2-trifluoro-acetyl)-amino]-N-hydroxy-benzamide 
• 86410-85-7 2,2,2-Trifluoro-N-hexadecyl-N-[4-(pyrrolidine-1-carbonyl)-phenyl]-acetamide 

Relevant academic research and scientific papers

Method of treating hyperlipidemia with 4-(monoalkylamino)benzoic acid amides

This disclosure describes a method of treating hyperlipidemia and atherosclerotic lesions with 4-(monoalkylamino)benzoic acid amides and compositions therefor.

Potential Antiatherosclerotic Agents. 3. Substituted Benzoic and Non Benzoic Acid Analogues of Cetaben

The synthesis of a series of analogues in which the carboxylic acid group of cetaben is replaced by carboxylate ester, carboxamide, or a variety of other substituent groups is described.Also reported are the syntheses of analogues in which the phenyl ring of cetaben is either modified by the presence of additional substituents or replaced entirely by another moiety.Structure-activity relationships of these compounds both as hypolipidemic agents and as inhibitors of the enzyme fatty acyl-CoA:cholesterol acyltransferase (ACAT) are discussed.Analogue syntheses designed to produce compounds that would be better absorbed orally than cetaben failed to yield any congeners of enhanced biological activity.In contrast, analogue syntheses directed toward non carboxylic acids of similar acidity to cetaben produced a very active class of sulfonamides.

Certain pyridyl esters of 4-(monoalkylamino) benzoic hydroxyalkanoic acids

This disclosure describes esters of 4-(monoalkylamino)benzoic acids with hydroxyalkanoic acids and derivatives, phenols, or 3-pyridinols useful as hypolipidemic agents.

2-Substituted-4'-(monoalkylamino)-acetophenones

This disclosure describes 2-substituted 4'-(monoalkylamino)-acetophenones useful as hypolipidemic and anti-atherosclerotic agents.

4-(Monoalkylamino)benzoic acid imidates

This disclosure describes 4-(monoalkylamino)benzoic acid amides and imidates useful as hypolipidemic and antiatherosclerotic agents.